Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini

Recent studies suggest that multiple myeloma is an immunogenic disease, which might be effectively targeted by antigen-specific T-cell immunotherapy. As standard of care in myeloma includes proteasome inhibitor therapy, it is of great importance to characterize the effects of this treatment on HLA-r...

Descripción completa

Detalles Bibliográficos
Autores principales: Kowalewski, D J, Walz, S, Backert, L, Schuster, H, Kohlbacher, O, Weisel, K, Rittig, S M, Kanz, L, Salih, H R, Rammensee, H-G, Stevanović, S, Stickel, J S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855252/
https://www.ncbi.nlm.nih.gov/pubmed/27058226
http://dx.doi.org/10.1038/bcj.2016.14

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855252/
https://www.ncbi.nlm.nih.gov/pubmed/27058226
http://dx.doi.org/10.1038/bcj.2016.14

Ejemplares similares